|
|
Managing Director - Menlo Park, California
|
 |
Patrick Enright is a founder and Managing Director of Longitude Capital. He focuses on investments in biotechnology.
From 2002 through 2006, Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Prior to Pequot, he was a Managing Member responsible for the Delta Opportunity Fund, where he invested in privately-held and publicly-traded biotechnology companies, such as SUGEN (acquired by Pharmacia) and Cephalon. Mr. Enright began his investment career at PaineWebber Development Corporation, a direct investment group focused primarily on biotechnology companies. Mr. Enright also has significant life sciences operations experience. He was CFO and Senior Vice President Business Development of Valentis, and Senior Vice President Finance and Business Development of Boehringer Mannheim Pharmaceuticals (now Hoffmann-La Roche). Mr. Enright began his life sciences career 24 years ago at Sandoz (now Novartis).
He currently serves on the boards of Corcept Therapeutics (NASDAQ: CORT), InfaCare Pharmaceuticals and Jazz Pharmaceuticals (NASDAQ: JAZZ). He has previously served on the boards of Codexis, DiObex Pharmaceuticals, Horizon Therapeutics, MAP Pharmaceuticals (NASDAQ: MAPP), Prestwick Pharmaceuticals, Threshold Pharmaceuticals (NASDAQ: THLD) and Sequenom (NASDAQ: SQNM).
Mr. Enright holds an M.B.A. from the Wharton School of Business at the University of Pennsylvania and a B.S. in Biological Sciences from Stanford University.
|
|
|
|
